Last reviewed · How we verify
Heparin sodium lock solution
Heparin sodium inhibits blood coagulation by potentiating antithrombin III, which inactivates thrombin and other clotting factors.
Heparin sodium inhibits blood coagulation by potentiating antithrombin III, which inactivates thrombin and other clotting factors. Used for Maintenance of central venous catheter patency (lock solution), Prevention of thrombosis in indwelling catheters.
At a glance
| Generic name | Heparin sodium lock solution |
|---|---|
| Also known as | Hep-Lock, Heparin, Hemofol (Traade Mark) |
| Sponsor | Hospital Civil de Guadalajara |
| Drug class | Anticoagulant |
| Target | Antithrombin III (indirect target); Thrombin and Factor Xa (downstream targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Thromboembolism Prevention |
| Phase | FDA-approved |
Mechanism of action
Heparin is an anticoagulant that works by binding to and enhancing the activity of antithrombin III, a natural inhibitor of blood coagulation. This complex inactivates several activated clotting factors (particularly thrombin and Factor Xa), preventing the formation and extension of blood clots. When used as a lock solution in catheters, it maintains catheter patency by preventing thrombosis within the device.
Approved indications
- Maintenance of central venous catheter patency (lock solution)
- Prevention of thrombosis in indwelling catheters
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Local catheter site reactions
Key clinical trials
- Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD) (PHASE4)
- Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients (NA)
- Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) (PHASE3)
- KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure (NA)
- Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age (PHASE4)
- Antimicrobial Locks for Hemodialysis Catheter Infections (PHASE2)
- Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection (PHASE3)
- Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin sodium lock solution CI brief — competitive landscape report
- Heparin sodium lock solution updates RSS · CI watch RSS
- Hospital Civil de Guadalajara portfolio CI